Liean S.

Senior Vice President, Head of Cmc @Acumen Pharmaceuticals, Inc

Plainfield, IN, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Feb 2025 — Present

Senior Vice President, Head of Cmc @Acumen Pharmaceuticals, Inc

View department →

US

EDUCATION

1996 — 1997

UCL

Msc, Biochemical Engineering

1992 — 1996

University of Kent

Bsc, Microbiology

SKILLS

GlpBiochemistryR&DBiochemical EngineeringDownstream ProcessingMonoclonal AntibodiesPharmaceutical IndustrySopFdaCell CultureRegulatory AffairsLifesciencesPurificationGmpRegulatory SubmissionsChromatographyLife SciencesMolecular BiologyBiosimilarsElisaProtein ChemistryCmcIndDrug DiscoveryClinical DevelopmentContract ManufacturingFermentationValidationHplcAnalytical ChemistryU.s. Food and Drug Administration (Fda)CellMammalian Cell CultureGxpAseptic ProcessingChemistryTechnology TransferCROCommercializationBiotechnology

ABOUT LIEAN S.

BIOCHEMICAL ENGINEER, PHARMACEUTICAL INDUSTRY LEADER, AND SCIENTIST with strong skill sets in all phases of drug product development and manufacturing,(drug development: biological e.g. Antibodies, Peptides, Small molecules e.g. chemistry synthetic routes, drug formulations). Also, I am adept at Six Sigma principles and data analysis with the ability to produce relevant insights supporting strategic business decisions and long-range program planning. I possess the ability to lead multiple cross-functional teams in a cohesive, strategic direction, while maintaining excellent communications, quality control and compliance.MY CAREER PASSION is blending my biochemical engineering expertise and leadership skills while applying them to the development of scientific projects.CAREER HIGHLIGHTS:• Submission of breakthrough designated Sarcoma treatment within 18 months of clinical data assessment showing an increase in life on 11months; launched within 8 days of US first approval, beat market forecast in sales of commercial supply in first year• Submission of breakthrough designated tumor agnostic cancer treatment with data showing up to 85% objective response rate for patients with RET altered mutations, significantly increasing their survival• Acquisition and Integration of Loxo Oncology and ImClone Systems, bringing new products (4 commercially approved) and drug development capabilities to expand and enhance drug development opportunitiesSKILLS AND EXPERTISE:Pharmaceutical ScientistProgram ManagementProject ManagementTeam LeadershipEarly Phase DevelopmentPortfolio ManagementCommercial LaunchMentor / CoachLate Phase DevelopmentNegotiation / InfluenceProcess DevelopmentSupervision / SMEAsset Due DiligenceContract AnalysisKey StakeholdersRisk ManagementVC Partnership RelationsGovernanceVendor SelectionAcquisitionsContinuous ImprovementSix Sigma Green BeltCMO OversightDrug DevelopmentBudget ManagementExternal Asset AnalysisIn-license ProductsStrategic Direction

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.